Clinical Trial Detail

NCT ID NCT03593226
Title Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Agalimmune Ltd.
Indications

Advanced Solid Tumor

Therapies

AGI-134

Age Groups: adult senior

No variant requirements are available.